This webinar will consider the current state of science in Alzheimer’s research, including what is known currently and what is on the horizon as more than 1,000 new people face a diagnosis each day. Attendees will hear from the Global Alzheimer’s Platform Foundation (GAP), whose inaugural study, Bio-Hermes, evaluated the ability of several promising blood-based and digital biomarkers to reflect brain amyloid PET scans in participants enrolled at clinical trial sites to determine if there is a relationship between the technologies used and identifying key hall markers of Alzheimer’s disease, enrolling an unprecedented number of people from racial and ethnic minority populations. All the data cannot be helpful without the critical eye of optimized data analysis, and Pentara Corporation will discuss the importance of quality data and how the Bio-Hermes data looks to stand up in this competitive environment.
Join the featured speakers as they review the findings from the Bio-Hermes study and talk about what this means for Alzheimer’s research at large.
Dr. Jeffrey Cummings, Director, Chambers-Grundy Center for Transformative Neuroscience, UNLV
Dr. Jeffrey Cummings, a world-renowned Alzheimer’s researcher and clinical trial leader is currently the Vice Chair of Research, UNLV Department of Brain Health. He is the Founding Director of the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, Nevada, and Professor of Medicine (Neurology), Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.
Dr. Richard Mohs, Chief Scientific Officer, Global Alzheimer’s Platform Foundation
Dr. Richard C. Mohs, PhD is the Chief Scientific Officer for the Global Alzheimer’s Platform Foundation (GAP), and is the Vice President for Clinical Development at Agenebio, a biotechnology company based in Baltimore. He also serves as a member of the Board of Governors for the Alzheimer’s Drug Discovery Foundation and is a member of the Board of Directors of Cogstate, Inc. He retired in 2015 from Eli Lilly and Company where he worked in several leadership positions for over a decade.
Dr. Suzanne Hendrix, CEO, Pentara Corporation
Dr. Suzanne Hendrix has worked as a clinical trial statistician and has now accumulated over 30 years of experience with time spent at CROs and pharmaceutical companies, including projects across many disease areas. Since becoming CEO of Pentara in 2008, Dr. Hendrix has maintained a central focus on analysis of clinical trials for degenerative diseases, especially Alzheimer’s disease (AD).
John Dwyer, President and CEO, Global Alzheimer’s Platform Foundation
John Dwyer is the President and CEO of the Global Alzheimer’s Platform Foundation (GAP) and is a serial healthcare entrepreneur. He is a co-founder of several Alzheimer’s-related groups including UsAgainstAlzheimer’s and the Alzheimer’s Action PAC, the first political action committee focused on a specific disease.
Who Should Attend?
- Drug developers (clinical scientists, data scientists, clinical operations)
- Patients (patient advocates, care partners)
- Healthcare practitioners
- Pharmaceutical companies involved seeking innovation in Alzheimer’s disease clinical trials
What You Will Learn
Attendees will gain insights into:
- Advances in most common blood and digital biomarkers for Alzheimer’s disease trials
- Statistical relationship between individual blood and digital biomarkers
- Relationship between blood-based biomarkers and Amyloid PET scans
Global Alzheimer’s Platform Foundation (GAP)
The Global Alzheimer’s Platform Foundation (GAP) is a patient-centric, non-profit organization dedicated to speeding the delivery of innovative therapies to those living with Alzheimer’s and Parkinson’s by reducing the time and cost of Alzheimer’s disease (AD) and Parkinson’s disease (PD) clinical trials.